Products Truvada
Truvada Approved Completed ⚡ Active Interest: 43/100
Sep 1, 2004 → Jan 1, 2007
About Truvada Truvada is a approved stage product being developed by Gilead Sciences for HIV-1 Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00323687. Target conditions include HIV-1 Infection.
What happened to similar drugs? 20 of 20 similar drugs in HIV-1 Infection were approved
Clinical Trials (5) NCT ID Phase Status Start Completion Indication NCT06631365 Phase 2 Recruiting Oct 2, 2023 Apr 1, 2025 HIV-1-infection NCT03512418 Phase 3 Completed Jun 20, 2019 Apr 10, 2024 HIV Infections NCT03842436 Approved Completed Oct 1, 2018 Apr 22, 2020 HIV/AIDS NCT02732730 Approved Completed Oct 12, 2016 Oct 25, 2018 HIV NCT00323687 Approved Completed Sep 1, 2004 Jan 1, 2007 HIV-1 Infection
Product Company Stage Hype Score DOR/ISL Merck Phase 2 SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo + SHR2150；Placebo Jiangsu Hengrui Medicine Phase 1 Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available AbbVie Approved lopinavir/ritonavir + lamivudine AbbVie Pre-clinical CVC 150 mg + CVC 300 mg AbbVie Phase 2 Doravirine, Tenofovir, Lamivudine - Blinded + Doravirine, Tenofovir, Lamivudine - Open-Label + ATRIPLA^TM + Placebo to ATRIPLA™ + Placebo to Doravirine, Tenofovir, Lamivudine Merck Phase 2 DOR/ISL + BIC/FTC/TAF + Placebo to BIC/FTC/TAF + Placebo to DOR/ISL Merck Phase 3 Vorinostat Merck Phase 1/2 Islatravir Merck Phase 1 Doravirine, Tenofovir, Lamivudine + Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor + Baseline regimen of cobicistat-boosted elvitegravir + Baseline regimen of a non-nucleoside reverse transcriptase inhibitor + Baseline regimen of two nucleoside reverse transcriptase inhibitors Merck Phase 3 raltegravir and etravirine Merck Phase 2 Treatment A: Doravirine 100 mg film coated tablet + Treatment B: Doravirine 150 mg tablet (40% drug loaded granule) + Treatment C: Doravirine 150 mg tablet (30% drug loaded granule) + Treatment D: Doravirine 150 mg tablet (50% drug loaded granule) + Treatment E: Doravirine 100 mg tablet (30% drug loaded granule) Merck Phase 1 ISL + ULO + BIC/FTC/TAF Merck Phase 2 Ulonivirine Merck Phase 1 Islatravir + Placebo to Islatravir + Doravirine + Placebo to Doravirine + Lamivudine + Placebo to Lamivudine + Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate + Doravirine/Islatravir Merck Phase 2 MK0518 (Raltegravir) + famotidine + omeprazole Merck Phase 1 Doravirine Merck Phase 1 MK-8510 Merck Phase 1 18F-Raltegravir Merck Phase 1 Pegylated Interferon alpha 2b Merck Phase 2